However, a multi-institutional historical cohort study suggested that salvage nivolumab plus ipilimumab and ipilimumab monotherapy showed limited efficacy in Japanese populations with advanced melanoma after PD1 resistance. This evidence concerns the gene PDCD1 and melanoma.